Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi®)

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations

Life Sciences, Genetics, Hematology +14

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +10

Skin Changes Secondary to Hydroxyurea Therapy

B. J. Kennedy · Archives of Dermatology · 1975 · 186 citations

Medicine, Dermatology, Pharmacotherapy +13

Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea

Mazen S. Daoud, Lawrence E. Gibson, Mark R. Pittelkow · Journal of the American Academy of Dermatology · 1997 · 138 citations

Medicine, Dermatology, Pathology +9